Apogenix Ag

Apogenix Gmbh

Abbvie Inc.

Affiris Ag

Christian Gieffers

Oliver Hill

Meinolf Thiemann

Tim Schnyder

Marcus Branschädel

Harald Fricke

Jaromir Sykora

Marcus Branschaedel

Marcus Branschadel

Christian Merz

Frank Mattner

Markus Mandler

Susan E Lappe

Andrea Dolischka

Fritz G Buchanan

Matilde Todaro

Giorgio Stassi

Carmen Fischer

Oleksandr Otava

Darren C Phillips

Marcus BRANSCHÄDEL

The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.

Light single-chain fusion polypeptides, encoding nucleic acid molecules and host cells

Provided herein are specific GITR receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a GITRL-associated disease or disorder. The GITR receptor agonist proteins provided herein comprise three soluble GITRL domains and an Fc fragment. The GITR receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.

Single-chain glucocorticoid-induced tumor necrosis factor receptor (GITR) receptor agonist proteins

The present invention relates to a specific CD95L antibody and to the use thereof in the treatment or diagnosis of diseases involving CD95L-induced signalling, e.g. cancer diseases.

Monoclonal anti-CD95L (cluster of differentiation 95 ligand) antibody

Provided herein are specific CD137 receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a CD137L-associated disease or disorder. The CD137 receptor agonist proteins provided herein comprise three soluble CD137L domains and an Fe fragment. The CD137 receptor agonist proteins are substantially non-aggregating and suitable for therapeuctic, diagnostic and/or research applications.

Single-chain CD137-receptor agonist proteins

Provided herein are specific CD27 receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a CD27L-associated disease or disorder. The CD27 receptor agonist proteins provided herein comprise three soluble CD27L domains an and Fc fragment. The CD27 receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.

Single-chain CD27-receptor agonist proteins

Provided herein are specific CD40 receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a CD40L-associated disease or disorder. The CD40 receptor agonist proteins provided herein comprise three soluble CD40L domains and an Fc fragment. The CD40 receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.

Single-chain CD40-receptor agonist proteins

Provided herein are specific TL1A receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a TL1A-associated disease or disorder. The TL1A receptor agonist proteins provided herein comprise three soluble TL1A domains and an Fc fragment. The TL1A receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.

Single-chain TL1A receptor agonist proteins

Provided herein are specific LIGHT receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a LIGHT-associated disease or disorder. The LIGHT receptor agonist proteins provided herein comprise three soluble LIGHT domains and an Fc fragment. The LIGHT receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.

Single-chain light receptor agonist proteins

CD27 ligand (CD27L) single-chain fusion polypeptides

Single-chain glucocorticoid-induced tumor necrosis factor receptor (GITR) agonist proteins

The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.

CD27L collectin fusion proteins and encoding nucleic acids

CD40L single-chain fusion polypeptides and encoding nucleic acids

Monoclonal anti-CD95L antibody

The present invention relates to an isolated fusion protein comprising an extracellular CD95 domain or a functional fragment thereof and an Fc domain or functional fragment thereof, formulations providing such fusion protein in a stable form as well as a method for producing such a fusion protein.

Nucleic acids encoding artificial signal peptides and methods of production thereof

The present invention relates to a specific CD95L antibody and to the use thereof in the diagnosis of a cancer disease.

Growing community of inventors

Dossenheim, Germany

Christian Gieffers